NASDAQ:TNXP - Tonix Pharmaceuticals Stock Price, News & Analysis

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Shares of Tonix Pharmaceuticals reverse split before market open on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) posted its quarterly earnings results on Monday, August, 12th. The company reported ($0.95) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.96) by $0.01. View Tonix Pharmaceuticals' Earnings History.

Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Tonix Pharmaceuticals.

1 equities research analysts have issued 1-year price objectives for Tonix Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they expect Tonix Pharmaceuticals' stock price to reach $4.00 in the next year. This suggests a possible upside of 788.9% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tonix Pharmaceuticals.

News coverage about TNXP stock has trended positive this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tonix Pharmaceuticals earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Tonix Pharmaceuticals.

Tonix Pharmaceuticals saw a decline in short interest during the month of July. As of July 31st, there was short interest totalling 471,300 shares, a decline of 45.5% from the June 30th total of 864,500 shares. Based on an average daily trading volume, of 555,700 shares, the days-to-cover ratio is presently 0.8 days. Approximately 20.3% of the shares of the stock are short sold. View Tonix Pharmaceuticals' Current Options Chain.

Some companies that are related to Tonix Pharmaceuticals include ContraFect (CFRX), Sophiris Bio (SPHS), DiaMedica Therapeutics (DMAC), AzurRx BioPharma (AZRX), Akari Therapeutics (AKTX), Aerpio Pharmaceuticals (ARPO), Acerus Pharmaceuticals (ASPCF), Vistagen Therapeutics (VTGN), Sernova (SEOVF), Citius Pharmaceuticals (CTXR), BIOLINERX LTD/S (BLRX), ProPhase Labs (PRPH), KemPharm (KMPH), Aytu Bioscience (AYTU) and Acer Therapeutics (ACER).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Rite Aid (RAD), Novavax (NVAX), SCYNEXIS (SCYX), Synthetic Biologics (SYN), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Nektar Therapeutics (NKTR) and Rigel Pharmaceuticals (RIGL).

Tonix Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.55%), Acadian Asset Management LLC (0.43%) and A.R.T. Advisors LLC (0.20%). Company insiders that own Tonix Pharmaceuticals stock include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.

TNXP stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Acadian Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals.

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TNXP stock can currently be purchased for approximately $0.45.

Tonix Pharmaceuticals has a market capitalization of $6.91 million. The company earns $-26,090,000.00 in net income (profit) each year or ($26.81) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe.View Additional Information About Tonix Pharmaceuticals.

The official website for Tonix Pharmaceuticals is http://www.tonixpharma.com/.

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]